An in vitro nanocarrier-based B cell antigen loading system; tumor growth suppression via transfusion of the antigen-loaded B cells in vivo

被引:0
作者
Kawaguchi, Yoshino [1 ]
Shimizu, Taro [1 ]
Takata, Haruka [1 ,2 ]
Ando, Hidenori [1 ,2 ]
Ishida, Tatsuhiro [1 ,2 ]
机构
[1] Tokushima Univ, Inst Biomed Sci, Dept Pharmacokinet & Biopharmaceut, 1-78-1,Sho Machi, Tokushima 7708505, Japan
[2] Tokushima Univ, Inst Biomed Sci, Innovat Res Ctr Drug Delivery Syst, Tokushima 7708505, Japan
基金
日本学术振兴会;
关键词
B cell-based vaccine; Antigen loading; Liposomes; Cancer; Complement system; KILLER T-CELLS; COMPLEMENT; LYMPHOCYTES; ACTIVATION; DELIVERY; IMMUNITY;
D O I
10.1016/j.ijpharm.2025.125189
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
B cell-based vaccines are expected to provide an alternative to DC-based vaccines. However, the efficacy of antigen uptake by B cells in vitro is relatively low, and efficient antigen-loading methods must be established before B cell-based vaccines are viable in clinical settings. We recently developed an in vitro system that efficiently loads antigens into isolated splenic B cells via liposomes decorated with hydroxyl PEG (HO-PEG-Lips). Therefore, the purpose of this study was to expand this system in order to achieve another approach to in vivo tumor growth suppression. By using HO-PEG-Lips as a carrier for model antigen OVA along with an adjuvant, alpha-galactosylceramide (GC), the amount of antigen loading to the B cells in vitro was increased compared with that of both free OVA and free GC. Transfusion of B cells treated with HO-PEG-Lips that encapsulated OVA and GC suppressed the growth of OVA-expressing murine thymoma (E.G7-OVA) tumors in vivo through strong induction of OVA-specific T cells. Under fluorescence microscopic observation, migration of the transfused B cells in the spleens of recipient mice were confirmed. Our results indicate that our novel antigen-loading system could become a promising approach to facilitate the development of cell-based therapeutic cancer vaccines utilizing B cells as alternative APCs.
引用
收藏
页数:9
相关论文
共 37 条
  • [1] The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
    Abakushina, Elena V.
    Popova, Liubov I.
    Zamyatnin, Andrey A., Jr.
    Werner, Jens
    Mikhailovsky, Nikolay V.
    Bazhin, Alexandr V.
    [J]. VACCINES, 2021, 9 (11)
  • [2] The Other Function: Class II-Restricted Antigen Presentation by B Cells
    Adler, Lital N.
    Jiang, Wei
    Bhamidipati, Kartik
    Millican, Matthew
    Macaubas, Claudia
    Hung, Shu-chen
    Mellins, Elizabeth D.
    [J]. FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [3] BARTLETT GR, 1959, J BIOL CHEM, V234, P469
  • [4] Complement and humoral immunity
    Carroll, Michael C.
    [J]. VACCINE, 2008, 26 : I28 - I33
  • [5] Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma
    Chu, Tan-Huy
    Vo, Manh-Cuong
    Park, Hye-Seong
    Lakshmi, Thangaraj Jaya
    Jung, Sung-Hoon
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (01) : 31 - 45
  • [6] CONTROL OF THE ANTITUMORAL ACTIVITY OF HUMAN MACROPHAGES PRODUCED IN LARGE AMOUNTS IN VIEW OF ADOPTIVE TRANSFER
    DUMONT, S
    HARTMANN, D
    POINDRON, P
    OBERLING, F
    FARADJI, A
    BARTHOLEYNS, J
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (11): : 1691 - 1698
  • [7] Dendritic cell subsets in T cell programming: location dictates function
    Eisenbarth, S. C.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2019, 19 (02) : 89 - 103
  • [8] Current Concepts of Antigen Cross-Presentation
    Embgenbroich, Maria
    Burgdorf, Sven
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [9] Therapeutic cancer vaccines: advancements, challenges, and prospects
    Fan, Ting
    Zhang, Mingna
    Yang, Jingxian
    Zhu, Zhounan
    Cao, Wanlu
    Dong, Chunyan
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [10] Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein
    Fujii, S
    Shimizu, K
    Smith, C
    Bonifaz, L
    Steinman, RM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (02) : 267 - 279